Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1813464 | 0.86 | HRH3 (0.63) | HRH3MAPK1HTTKCNH2 | |
| SCHEMBL1809300 | 0.85 | HRH3 (0.62) | HRH3MAPK1HTTKCNH2 | |
| SCHEMBL1808788 | 0.81 | DRD2 (0.41) | HRH3HTT | |
| SCHEMBL1813029 | 0.79 | HRH3 (0.76) | HRH3KCNH2 | |
| SCHEMBL1810788 | 0.79 | HRH3 (0.76) | HRH3KCNH2 | |
| SCHEMBL1815146 | 0.76 | HRH3 (0.78) | HRH3KCNH2 | |
| SCHEMBL4166236 | 0.70 | MAPK1 (0.43) | HRH3MAPK1HTTKCNH2ADAM17 | |
| SCHEMBL1811370 | 0.69 | HRH3 (0.46) | HRH3KCNH2 | |
| SCHEMBL7586080 | 0.68 | CCR5 (0.67) | MAPK1HTTCYP2D6CCR5 | |
| SCHEMBL1812799 | 0.68 | HRH3 (0.56) | HRH3KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935719-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2011-05-03 | — | — | US | claimed |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-05-22 | — | — | US | claimed |
| US-7935719-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935719-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935719-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
| WO-2008045371-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | HNMT, HRH4, HRH3 | HRH3 3/4885MAPK1 2641/4885HTT 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.